<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00894114</url>
  </required_header>
  <id_info>
    <org_study_id>V520-019</org_study_id>
    <secondary_id>2009_585</secondary_id>
    <nct_id>NCT00894114</nct_id>
  </id_info>
  <brief_title>A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)</brief_title>
  <official_title>A Probe Study of the Safety, Tolerability, and Immunogenicity of a 1-Dose Regimen of the MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC-HIV (vCP205) Vaccine in Healthy Adults Who Previously Received a 3-Dose Regimen of MRKAd5, Ad5, or Placebo in Merck V520 Protocols 007 or 012</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This study is designed to determine whether patients previously primed with Ad5 of MRKAd5
      HIV-1 gag vaccine respond better when boosted with ALVAC-HIV vaccine than when boosted with
      MKRAd5 HIV-1 gag vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of ALVAC-HIV or MRKAd5 HIV-1 vaccine in subjects who previously received a 3-dose regimen of Ad5 HIV-1 gag vaccine measured by number of injection-site adverse experiences (AE), non serious systemic AE, lab AE, serious AE.</measure>
    <time_frame>Injection-site AE up to 5 days after vaccination, non-serious systemic AE and Lab AE up to 29 days after vaccination, serious AE for the entire study period (Week 260).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>immunogenicity of a single-dose regimen of the ALVAC-HIV vaccine or MRKAd5 HIV-1 vaccine measured by various assays</measure>
    <time_frame>4 weeks following vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Stratum 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo recipients in the parent protocol (Merck V520 Protocols 007 or 012) will receive ALVAC-HIV Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nonresponders who received active vaccine in parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low responders who received active vaccine in the parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High responders who received active vaccine in the parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V520</intervention_name>
    <description>MRKAd5 HIV-1 gag vaccine, a single dose 1.0 mL intramuscular injection</description>
    <arm_group_label>Stratum 2</arm_group_label>
    <arm_group_label>Stratum 3</arm_group_label>
    <arm_group_label>Stratum 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: ALVAC-HIV vaccine</intervention_name>
    <description>A single dose 0.1 intramuscular injection</description>
    <arm_group_label>Stratum 1</arm_group_label>
    <arm_group_label>Stratum 2</arm_group_label>
    <arm_group_label>Stratum 3</arm_group_label>
    <arm_group_label>Stratum 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject was previously enrolled in Merck HIV Vaccine study V520 Protocol 007 or 012,
             and received the complete 3-dose regimen during participation

          -  Subject is in good general health

          -  Subject is not infected with HIV

          -  Subject agrees not to donate blood during the first 52 weeks of the study

          -  Subject agrees not to donate sperm during the first 12 weeks of the study

          -  Subject who is of reproductive potential agrees to use an acceptable method of birth
             control through Week 12 of the study

        Exclusion Criteria:

          -  Subject has been administered immune globulin or blood product 3 months prior to
             receiving study vaccination

          -  Subject has been vaccinated with a live virus vaccine in the past 30 days

          -  Subject has been vaccinated with an inactivated vaccine in the past 14 days

          -  Subject has an active medical disease

          -  Subject is taking daily required prescription drugs

          -  Female subject is pregnant, breastfeeding or expecting to conceive

          -  Subject is positive for HIV

          -  Subject has used injection drug within the past year

          -  Subject has a sexual partner that is infected with HIV

          -  Subject has a sexual partner that is an active injection drug user

          -  Subject has been treated for or diagnosed with a new sexually transmitted disease in
             the past 6 months

          -  Subject engaged in unprotected intercourse with more than 2 persons in the previous 6
             months

          -  Subject engaged in protected intercourse with more than 4 persons in the previous 6
             months

          -  Subject has previously participated in an HIV vaccine clinical trial (other than Merck
             V520 Protocols 007 and 012)

          -  Subject weighs less than 110 lbs.

          -  Subject has a recent history of alcohol abuse

          -  Subject intends to donate blood in the first 52 weeks of the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2009</study_first_submitted>
  <study_first_submitted_qc>May 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2009</study_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

